{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:54:41Z","timestamp":1755795281321,"version":"3.44.0"},"reference-count":37,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>On the one hand, the primary coronary slow flow phenomenon (CSFP) can cause recurrence of chest pain, prompting medical examinations and further healthcare costs, while on the other hand, it can lead to myocardial infarction, ventricular arrhythmia and sudden cardiac death. Nevertheless, there is not any agreement on the optimal treatment for primary CSFP, so we decided to examine the effectiveness of sildenafil in this context.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This pilot study is a 12-week, triple-blind, randomised, placebo-controlled trial for receiving either 50\u2009mg daily oral sildenafil or placebo. Twenty eligible patients aged 30\u201370 years from a tertiary hospital in Yazd were randomly allocated in a 1:1 ratio to two groups. The primary outcomes were the alterations in functional capacity (metabolic equivalents, METs), Duke treadmill score (DTS) and angina severity (Canadian Cardiovascular Society (CCS) class). The study protocol registration code is IRCT20220223054103N1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The angina severity in the Sildenafil group improved, with all receivers achieving a state of being asymptomatic during regular physical activity (CCS I). Whereas just 40% of the recipients in the placebo group achieved the same level of improvement (p=0.011). Mean METs at baseline were 9.9 (SD: 3.1) and at week 12 were 13.1 (SD: 3.3) for sildenafil and 9.56 (SD: 2.1) and 9.63 (SD: 2.4) for placebo (difference favouring sildenafil with a median increase of 3.1 (IQR: 1.1 to 4.1, p=0.008)). Median DTS scores at baseline were 3 (IQR: 0 to 9) and at week 12 were 9.5 (IQR: 7.75 to 15) for sildenafil and 7 (IQR: \u22121.5 to 9.25) and 8 (IQR: 1.5 to 11.25) for placebo (difference favouring sildenafil with a median increase of 5.5 (IQR: 1 to 9.2, p=0.01)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We suggest that a daily low dose of sildenafil could be a valuable therapeutic option for primary CSFP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>IRCT20220223054103N1.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2024-002772","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T03:00:11Z","timestamp":1724986811000},"page":"e002772","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Sildenafil\u2019s effectiveness in the primary coronary slow flow phenomenon: a pilot randomised controlled clinical trial"],"prefix":"10.1136","volume":"11","author":[{"given":"Abbas","family":"Andishmand","sequence":"first","affiliation":[{"name":"Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedmostafa","family":"Seyedhosseini","sequence":"additional","affiliation":[{"name":"Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedeh Mahdieh","family":"Namayandeh","sequence":"additional","affiliation":[{"name":"Epidemiologist, Associated Professor, Afshar Research Development Center, Yazd, Iran"},{"name":"Center for Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnaz","family":"Adelzadeh","sequence":"additional","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Entezari","sequence":"additional","affiliation":[{"name":"Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-201X","authenticated-orcid":false,"given":"Seyed Reza","family":"Mirjalili","sequence":"additional","affiliation":[{"name":"Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,8,25]]},"reference":[{"key":"2025081709295454000_11.2.e002772.1","first-page":"37","article-title":"The coronary slow flow phenomenon: characteristics, mechanisms and implications","volume":"1","author":"Wang","year":"2011","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025081709295454000_11.2.e002772.2","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2021.46","article-title":"Slow Coronary Blood Flow: Pathogenesis and Clinical Implications","volume":"17","author":"Aparicio","year":"2022","journal-title":"Eur Cardiol"},{"key":"2025081709295454000_11.2.e002772.3","first-page":"462","article-title":"Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias","volume":"16","author":"Wozakowska-Kap\u0142on","year":"2009","journal-title":"Cardiol J"},{"key":"2025081709295454000_11.2.e002772.4","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20266"},{"key":"2025081709295454000_11.2.e002772.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2023.01.008"},{"key":"2025081709295454000_11.2.e002772.6","first-page":"289","article-title":"Effect of slow coronary flow on electrocardiographic parameters reflecting ventricular heterogeneity","volume":"58","author":"Sezgin","year":"2007","journal-title":"Angiol Open Access"},{"key":"2025081709295454000_11.2.e002772.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1542-474X.2003.08203.x"},{"key":"2025081709295454000_11.2.e002772.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-010-0058-4"},{"key":"2025081709295454000_11.2.e002772.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038851","article-title":"A Randomized, Single-Center Double-Blinded Trial on the Effects of Diltiazem Sustained-Release Capsules in Patients with Coronary Slow Flow Phenomenon at 6-Month Follow-Up","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"2025081709295454000_11.2.e002772.10","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e318279b7f6"},{"key":"2025081709295454000_11.2.e002772.11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.25270\/jic\/18.00250","article-title":"The Spontaneous Coronary Slow-Flow Phenomenon: Reversal by Intracoronary Nicardipine","volume":"31","author":"Mehta","year":"2019","journal-title":"J Invasive Cardiol"},{"key":"2025081709295454000_11.2.e002772.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.03.055"},{"key":"2025081709295454000_11.2.e002772.13","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.50.545"},{"key":"2025081709295454000_11.2.e002772.14","first-page":"244","article-title":"Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow","volume":"38","author":"Ak\u00e7ay","year":"2010","journal-title":"Turk Kardiyol Dern Ars"},{"key":"2025081709295454000_11.2.e002772.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2006.09.070"},{"key":"2025081709295454000_11.2.e002772.16","doi-asserted-by":"publisher","DOI":"10.1159\/000109405"},{"key":"2025081709295454000_11.2.e002772.17","doi-asserted-by":"publisher","DOI":"10.2165\/11537280-000000000-00000"},{"key":"2025081709295454000_11.2.e002772.18","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415571457"},{"key":"2025081709295454000_11.2.e002772.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007053230106"},{"key":"2025081709295454000_11.2.e002772.20","article-title":"Coronary Slow Flow Phenomenon Clinical Findings and Predictors","volume":"5","author":"Sanati","year":"2016","journal-title":"Res Cardiovasc Med"},{"key":"2025081709295454000_11.2.e002772.21","unstructured":"Dhaliwal A , Gupta M . PDE5 Inhibitors. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023. StatPearls Publishing LLC, 2023."},{"key":"2025081709295454000_11.2.e002772.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.11.009"},{"key":"2025081709295454000_11.2.e002772.23","doi-asserted-by":"crossref","unstructured":"Ashcroft RE . The declaration of helsinki. the oxford textbook of clinical research ethics. 2008: 141\u20138.","DOI":"10.1093\/oso\/9780195168655.003.0014"},{"key":"2025081709295454000_11.2.e002772.24","first-page":"371","article-title":"The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later","volume":"18","author":"Campeau","year":"2002","journal-title":"Can J Cardiol"},{"key":"2025081709295454000_11.2.e002772.25","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.5.879"},{"key":"2025081709295454000_11.2.e002772.26","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0205"},{"key":"2025081709295454000_11.2.e002772.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011858"},{"key":"2025081709295454000_11.2.e002772.28","unstructured":"Sealed envelope. 2023. Available: https:\/\/www.sealedenvelope.com\/"},{"key":"2025081709295454000_11.2.e002772.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(76)80401-2"},{"key":"2025081709295454000_11.2.e002772.30","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2006.1"},{"key":"2025081709295454000_11.2.e002772.31","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.16.1622"},{"key":"2025081709295454000_11.2.e002772.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2466"},{"key":"2025081709295454000_11.2.e002772.33","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20935"},{"key":"2025081709295454000_11.2.e002772.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-44190-7","article-title":"Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"2025081709295454000_11.2.e002772.35","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318804618"},{"key":"2025081709295454000_11.2.e002772.36","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/j.ihj.2018.06.001","article-title":"Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: A single centre experience","volume":"70 Suppl 3","author":"Sanghvi","year":"2018","journal-title":"Ind Heart J"},{"key":"2025081709295454000_11.2.e002772.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m3222","article-title":"Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis","volume":"370","author":"Luo","year":"2020","journal-title":"BMJ"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2024-002772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:30:07Z","timestamp":1755448207000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2024-002772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,25]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/openhrt-2024-002772"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2024-002772","relation":{},"ISSN":["2053-3624"],"issn-type":[{"type":"electronic","value":"2053-3624"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}